The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 

Characterization of 5-hydroxytryptamine receptors in the cranial vasculature.

The availability of selective compounds has made it possible to subdivide 5-hydroxytryptamine (5-HT) receptors into three distinct types, called 5-HT1-like, 5-HT2 and 5-HT3. The selective agonists at the three receptor types are, respectively, 5-carboxamidotryptamine, alpha-methyl-5-HT and 2-methyl-5-HT. While no selective antagonists are yet available for the 5-HT1-like receptors, some compounds, including ketanserin and MDL 72222, selectively antagonize 5-HT2 and 5-HT3 receptors respectively. Depending upon experimental conditions, 5-HT causes a constriction or dilatation of cerebral and extracerebral cranial vessels. Vascular contraction by 5-HT seems to be mediated primarily via 5-HT2 receptors (located mainly on large conducting vessels), though in several instances (for example, dog and human basilar arteries and porcine arteriovenous anastomoses; AVAs) 5-HT1-like receptors are involved in addition to or in place of 5-HT2 receptors. In the rabbit ear and external carotid arteries 5-HT may act directly on alpha-adrenoceptors. Arteriolar dilatation, leading to increased capillary ("nutrient") blood flow, occurs via 5-HT1-like receptors. However, the 5-HT1-like receptors on the arterioles and AVAs appear to be similar but not identical. Since a reduction of plasma 5-HT and opening of AVAs have been implicated in the pathophysiology of migraine, compounds acting on 5-HT1-like receptors to close the shunt vessels can be expected to have therapeutic activity in migraine.[1]

References

  1. Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Saxena, P.R., Bom, A.H., Verdouw, P.D. Cephalalgia : an international journal of headache. (1989) [Pubmed]
 
WikiGenes - Universities